Year: 2025
Type: editorial
Abstract: The epicutaneous peanut immunotherapeutic VP250 (Viaskin, DBV Technologies) was safe with increased efficacy at the 3-y mark in an open-label extension of the Phase 3 EPITOPE trial involving >200 t...
Authors: Ronald Ellis, Adam Weiss
Institution: Taylor and Francis (United Kingdom)
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,175
OpenAlex ID: W4407327541